3SBio, Inc. (ADR) (NASDAQ:SSRX)
The Company is engaged in the research, development, manufacture and distribution of pharmaceutical products in the China.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
High Volume Breakout on 02/08/13
Recs
Since this is CAPS, I'm taking 3SBio at their word regarding their 18M quarterly revenues and expected 20-30% topline growth in 2011. In the real world, I will not likely ever invest in a company based in China again.
Recs
Earnings are accelerating
Recs
This is a small/mid cap high growth stock that should outperform the S&P during the bull market.
Recs
SSRX grows because NKBP decreases. NKBP is the Chinese box of false returns
Recs
CHINA FINANCE, INC.
57-71 #HIGH-TECH INDUSTRIAL PARK NANSHAN,
DISTRICT SHENZHEN, P.R. CHINA 51805
October 11th 2004
RE: Resignation of XIAOBIN LIU
To the Board of Directors and Shareholders:
I hereby resign the position as the CFO of China Finance, Inc. (the "Company") effective immediately. Please be advised that my resignation from the Company is not a result of any disagreements with the Company on any matters relating to the Company's operations, policies, or practices. Please also be advised that I have no claim against the Company for compensation for loss of office, fees or disbursements or otherwise whatsoever.
Recs
Healthcare reform ---- in China!
Appreciating RMB vs USD...
Gaining exclusive rights to new drugs in China...
Growing a valuable marketing/distribution network...
A more lenient and "guangxi" centered regulatory system than FDA....
Rocketing sales and low P/E for a PROFITABLE biotech...
Fundamentals of a aging population of savers getting wealthier by the day...
Risky... yes, but I will take my chances.
Recs
Biotech stocks scare me with their drastic changes based on what seem to be minor news and simply their general unpredictability. However, it does appear that this company is a great growth opportunity, and a Fool writer seems to agree ("The Cheapest Stocks I Know"). So, though I'm generally a value investor, I'm taking a stab at this growth opportunity.
Recs
It's where the boom seems to be...
Recs
On every fundamental basis this company is cheap. From a growth perspective it is VERY cheap. Management seems to have a better track on managing in an economy and market that most do not understand and have dome a remarkable job in growing it conservatively to date - a sign of good management. There seems to be a great deal of respect to equity holders and manage their balance sheet accordingly. Stock looks like an easy double from these levels near term as the market regains its feet.
Recs
Recs
Small Chinese Pharmaceutical Seems promising with possible upcoming product releases. - J.P. Germanics
Recs
3 to 5 star stock in one year.
Recs
Theft via replication. Never put real money into it but in todays world I think they will prosper.
Recs
ONly young once.
Recs
Ouch, I bought into this bad boy back during the October China buy-spree. If it dips below 8 again, I may sell. Otherwise hold on for a while and hope to break even some months down the line...
Recs
3SBio has drugs on the market, drugs in the pipeline, future projects, and is continuing to seek markets in other countries; all of which, add up to growth.
Recs
Undervalued, Good Fundamentals
Recs
SSRX has good fundamentals at a low price. See you at $12.
Recs
Testing out a portfolio of smallish-cap 5-star stocks found using the CAPS screener. All picks have at least 50 allstars backing them, which should be enough to minimize star rating fluctuations. It's been less than a week, but so far so good!
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 48 : 1 2 3 Next »